Centessa Pharmaceuticals Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
129
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$7.8B
- Investors
-
1
Centessa Pharmaceuticals General Information
Description
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Contact Information
Website
www.centessa.comCorporate Office
- 3rd Floor 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Corporate Office
- 3rd Floor 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Centessa Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 24-Jun-2026 | $7.8B | Completed | Generating Revenue | ||
| 6. 2PO | 14-Nov-2025 | Completed | Generating Revenue | |||
| 5. Debt Refinancing | 30-Dec-2024 | Completed | Generating Revenue | |||
| 4. 2PO | 13-Sep-2024 | Completed | Generating Revenue | |||
| 3. 2PO | 25-Apr-2024 | Completed | Generating Revenue | |||
| 2. IPO | 28-May-2021 | $330M | $552M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC (Series A) | 29-Jan-2021 | $222M | $222M | Completed | Clinical Trials - General |
Centessa Pharmaceuticals Comparisons
Industry
Financing
Details
Centessa Pharmaceuticals Competitors (7)
One of Centessa Pharmaceuticals’s 7 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| BridgeBio Pharma | Formerly VC-backed | Palo Alto, CA | ||||
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Cullinan Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Roivant Sciences | Formerly PE-Backed | New York, NY |
Centessa Pharmaceuticals Signals
Centessa Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oberland Capital | PE/Buyout | Minority |
Centessa Pharmaceuticals Acquisitions (10)
Centessa Pharmaceuticals’s most recent deal was a Merger/Acquisition with Morphogen-IX. The deal was made on 23-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Morphogen-IX | 23-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Capella BioScience | 16-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Inexia | 16-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Orexia | 16-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| PearlRiver Bio | 16-Feb-2021 | Merger/Acquisition | Drug Discovery |
Centessa Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated April, 30, 2023
34.66 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,669
Rank
Percentile
Pharmaceuticals
Industry
of 895
Rank
Percentile
Pharmaceuticals
Subindustry
of 431
Rank
Percentile
Centessa Pharmaceuticals Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Inexia | London, United Kingdom | 2018 | |
| Orexia | London, United Kingdom | 2018 | |
| Morphogen-IX | Cambridge, United Kingdom | 2015 | |
| Z Factor | Cambridge, United Kingdom | 2015 | |
| Capella BioScience | London, United Kingdom | 2014 |
Centessa Pharmaceuticals FAQs
-
When was Centessa Pharmaceuticals founded?
Centessa Pharmaceuticals was founded in 2019.
-
Where is Centessa Pharmaceuticals headquartered?
Centessa Pharmaceuticals is headquartered in Altrincham, United Kingdom.
-
What is the size of Centessa Pharmaceuticals?
Centessa Pharmaceuticals has 129 total employees.
-
What industry is Centessa Pharmaceuticals in?
Centessa Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Centessa Pharmaceuticals a private or public company?
Centessa Pharmaceuticals is a Private company.
-
What is the current valuation of Centessa Pharmaceuticals?
The current valuation of Centessa Pharmaceuticals is .
-
What is Centessa Pharmaceuticals’s current revenue?
The current revenue for Centessa Pharmaceuticals is .
-
How much funding has Centessa Pharmaceuticals raised over time?
Centessa Pharmaceuticals has raised $1.36B.
-
Who are Centessa Pharmaceuticals’s investors?
Oberland Capital has invested in Centessa Pharmaceuticals.
-
Who are Centessa Pharmaceuticals’s competitors?
ORIC Pharmaceuticals, BridgeBio Pharma, Black Diamond Therapeutics, Cullinan Therapeutics, and Roivant Sciences are some of the 7 competitors of Centessa Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process